Australia Medicinal Cannabis Driving Laws: State-by-State Guide and Legal Framework

Executive Summary

Australia's medicinal cannabis driving laws create a legal paradox where patients prescribed cannabis for legitimate medical conditions face criminal prosecution for driving with any detectable THC in their system, regardless of impairment. Unlike alcohol, which uses evidence-based blood alcohol concentration limits, Australian states and territories apply zero-tolerance drug driving laws that detect THC metabolites days or weeks after use, long after psychoactive effects have subsided. This framework has sparked intense debate across Australia, with New South Wales emerging as a focal point in June 2026 as advocacy groups, medical professionals, and patients demand reform. The conflict centers on whether current roadside drug testing regimes protect public safety or unfairly criminalize approximately 250,000 Australians with legal medicinal cannabis prescriptions. The issue affects patient compliance, employment, and daily mobility while raising fundamental questions about evidence-based drug policy, federalism, and the balance between road safety and medical rights.

The controversy intensified in early June 2026 when New South Wales parliamentary debates highlighted the growing divide between medical cannabis policy and traffic enforcement. Patients report abandoning prescribed treatments due to fear of losing their driver's licenses, while road safety advocates warn against any relaxation of drug driving standards. The economic stakes are substantial: Australia's medicinal cannabis market reached AU$350 million in 2025, with projections exceeding AU$1.2 billion by 2028. Resolution of this conflict will determine whether Australia's medicinal cannabis framework can function practically or remains undermined by contradictory enforcement regimes.

Why This Matters

The intersection of medicinal cannabis access and driving laws affects hundreds of thousands of Australians while setting precedents for how nations balance emerging medical treatments with public safety enforcement. As of June 2026, approximately 250,000 Australians hold valid prescriptions for medicinal cannabis products under the Therapeutic Goods Administration Special Access Scheme and Authorised Prescriber pathways. The majority of these patients live in regional and rural areas where personal vehicle transport is not optional but essential for employment, medical appointments, and daily life.

The stakeholder landscape spans multiple sectors. Patients with chronic pain, epilepsy, multiple sclerosis, and cancer-related symptoms face impossible choices between legal medical treatment and maintaining their ability to drive. Medical practitioners report that driving law concerns significantly impact prescribing decisions, with many doctors reluctant to prescribe cannabis products to patients who drive for work. The Australian Medical Association has documented cases where patients discontinued effective treatments specifically due to driving law conflicts.

Employers in transport, logistics, construction, and mining sectors face compliance challenges. Companies must navigate workplace drug testing policies, duty-of-care obligations, and discrimination law while employees hold legal prescriptions. The Transport Workers Union estimates that over 15,000 commercial vehicle operators could benefit from medicinal cannabis for chronic conditions but cannot access treatment without losing their livelihoods.

Law enforcement agencies conduct approximately 5 million roadside drug tests annually across Australia, with cannabis detection rates around 1.5-2%. The New South Wales Police Force alone conducted 212,000 mobile drug tests in 2025. Police unions have consistently opposed any changes to zero-tolerance frameworks, arguing that impairment testing technology remains unreliable and that current laws provide clear enforcement standards.

The insurance industry holds significant financial stakes. The Insurance Council of Australia has warned that any shift away from zero-tolerance could complicate liability determinations in accident claims. Conversely, patient advocacy groups argue that current laws create perverse incentives where patients may choose black market products to avoid prescription records that could be used against them in traffic stops.

Background and History

Australia's medicinal cannabis driving law conflict emerged from the collision of progressive medical access reforms with decades-old zero-tolerance drug driving enforcement frameworks designed for illicit substance use.

Origins of Drug Driving Laws (1999-2004)

Victoria became the first Australian jurisdiction to introduce roadside drug testing in December 2004, following trials that began in 1999. The Victorian Road Safety Act 1986 was amended to create offenses for driving with any detectable presence of THC, methylamphetamine, or MDMA. The framework was explicitly zero-tolerance, modeled on the success of random breath testing for alcohol but without equivalent impairment thresholds. The Victorian Parliament's rationale centered on deterrence and ease of enforcement rather than demonstrated correlation between THC presence and crash risk.

New South Wales followed in 2007 with amendments to the Road Transport Act 2013 (then the Road Transport (Safety and Traffic Management) Act 1999). The NSW framework created strict liability offenses under sections 111-112, making it an offense to drive with prescribed illicit drugs present in oral fluid, blood, or urine. THC was classified alongside methamphetamine and MDMA, with no distinction for medical use or impairment levels. Queensland, South Australia, Western Australia, Tasmania, and the Northern Territory implemented similar regimes between 2007 and 2014.

Medicinal Cannabis Legalization (2016)

The federal Narcotic Drugs Amendment Act 2016 created Australia's legal medicinal cannabis framework, effective November 2016. The legislation amended the Narcotic Drugs Act 1967 to allow cultivation and manufacture of cannabis for medical and scientific purposes. The Therapeutic Goods Administration simultaneously created access pathways through Special Access Scheme Category B (individual patient applications) and Authorised Prescriber mechanisms.

Critically, the 2016 federal reforms did not address state and territory traffic laws. The Commonwealth Department of Health's explanatory memorandum acknowledged that "driving laws remain a matter for state and territory governments" but did not recommend coordinated reform. This created immediate legal tension: patients could legally possess and use cannabis under federal therapeutic frameworks while simultaneously committing strict liability traffic offenses under state laws.

Early Legal Challenges (2017-2020)

The first significant legal challenge emerged in South Australia in 2018. In Police v Carrall, a medicinal cannabis patient challenged a drug driving conviction, arguing that the prescription created a reasonable excuse defense. The South Australian Magistrates Court rejected this argument, finding that the Road Traffic Act 1961 created absolute liability with no medical exemption. The decision established precedent that legal prescription provides no defense to drug driving charges.

Tasmania became the first jurisdiction to acknowledge the conflict in 2019. The Tasmanian Government commissioned a review by the Department of Justice, which recommended maintaining zero-tolerance but improving patient education. The review found insufficient evidence that therapeutic cannabis doses impaired driving but concluded that detection technology could not distinguish between impairing and non-impairing THC levels.

Parliamentary Inquiries and Reviews (2020-2023)

The Victorian Parliament's Law Reform, Road and Community Safety Committee launched a comprehensive inquiry in August 2020, receiving over 140 submissions. The committee's March 2022 report, "Inquiry into Drug Law Reform," recommended that Victoria "consider options for reform" but stopped short of specific proposals. The report documented extensive patient testimony about treatment abandonment and noted that zero-tolerance laws may actually reduce road safety by discouraging patients from legal, quality-controlled products.

The New South Wales Parliament's Joint Standing Committee on Road Safety conducted parallel investigations in 2021-2022. The committee heard evidence from the Centre for Accident Research and Road Safety Queensland, which presented data showing no statistically significant increase in crash risk for drivers with low THC levels (below 5 ng/mL blood concentration). However, the committee's November 2022 report recommended no changes, citing law enforcement concerns and technological limitations.

The Tasmanian Exemption Experiment (2023)

Tasmania broke from national consensus in May 2023 when the Road Safety (Alcohol and Drugs) Amendment Act 2023 created a limited medical defense. The legislation allowed drivers with valid medicinal cannabis prescriptions to present evidence that they were not impaired at the time of driving. However, implementation proved problematic. The burden of proof remained on defendants, requiring expensive expert testimony. In the first 18 months, only three defendants successfully used the defense, while conviction rates for medicinal cannabis patients remained above 85%.

Federal Government Position Shift (2024-2025)

The Australian Government's position evolved significantly in 2024. In March 2024, Federal Health Minister Mark Butler announced a National Medicinal Cannabis Review, including examination of "barriers to patient access, including interactions with state driving laws." The review's interim report in September 2024 found that driving law concerns were the second-most cited reason for patients discontinuing medicinal cannabis treatment, affecting approximately 35% of patients who ceased use.

The Therapeutic Goods Administration released updated guidance in February 2025, explicitly warning prescribers to inform patients about drug driving laws. The guidance noted that "patients should be advised that legal possession of medicinal cannabis does not provide exemption from state and territory drug driving offenses" and recommended doctors consider "patient driving requirements when determining treatment suitability."

New South Wales Debate Intensifies (2026)

The current controversy reached peak intensity in June 2026 when the New South Wales Parliament debated a private member's bill proposing an impairment-based testing regime. The Medicinal Cannabis Patients (Road Safety) Bill 2026, introduced by independent MP Alex Greenwich, would replace zero-tolerance detection with functional impairment assessment for patients holding valid prescriptions. The bill proposed a two-tier system: roadside screening would continue, but patients with prescriptions could request secondary impairment testing including standardized field sobriety tests and cognitive assessment.

The debate divided the NSW Parliament along unexpected lines. The Labor government expressed openness to reform while emphasizing the need for reliable impairment testing technology. The Coalition opposition split, with some members supporting patient rights and others defending zero-tolerance. The NSW Police Association strongly opposed any changes, with President Kevin Morton stating that "any detectable THC represents unacceptable risk" and that impairment testing would create "unworkable enforcement burdens."

Key Players

Therapeutic Goods Administration (TGA)

The TGA regulates medicinal cannabis access at the federal level through the Special Access Scheme and Authorised Prescriber pathways. As of May 2026, the TGA had approved 487 Authorised Prescribers and processed over 380,000 individual patient applications since 2016. The agency maintains that its role is limited to therapeutic safety and efficacy, with road safety remaining a state responsibility. However, the TGA's February 2025 prescriber guidance acknowledged that driving law conflicts create "significant barriers to appropriate patient access."

National Transport Commission (NTC)

The NTC coordinates transport policy across Australian jurisdictions. In 2024, the Commission established a working group to examine medicinal cannabis driving issues, bringing together state and territory transport agencies. The working group's April 2025 discussion paper outlined three potential reform models: maintaining zero-tolerance with improved patient education, creating prescription-based exemptions with impairment testing, or establishing THC concentration thresholds similar to blood alcohol limits. The Commission has not yet released formal recommendations.

Medicinal Cannabis Industry Australia (MCIA)

MCIA represents over 60 licensed cultivators, manufacturers, and distributors. The industry group has actively lobbied for driving law reform, arguing that current frameworks undermine the commercial viability of the medicinal cannabis sector. MCIA's economic modeling suggests that driving law concerns suppress patient numbers by 40-50%, representing AU$400-500 million in foregone annual market value. The organization has funded research into impairment testing technologies and proposed industry-funded pilot programs.

Australasian College of Road Safety (ACRS)

ACRS has taken a nuanced position, acknowledging both patient rights and safety concerns. The College's 2025 position paper recommended that jurisdictions "develop evidence-based approaches that distinguish between THC presence and driving impairment" while maintaining that "any reform must be supported by reliable roadside impairment testing." ACRS has called for substantial research investment before policy changes.

Australian Medical Association (AMA)

The AMA has advocated for reform since 2023, with particular emphasis on the conflict between clinical judgment and legal liability. AMA President Professor Steve Robson stated in May 2026 that "doctors should be able to prescribe appropriate treatments without patients facing automatic criminalization for normal daily activities." The AMA's position supports impairment-based testing frameworks and has proposed that medical practitioners should be able to provide certification of patient fitness to drive, similar to frameworks for other medications affecting cognition.

Police Federations and Associations

Law enforcement unions across all jurisdictions have consistently opposed reform. The Australian Federal Police Association, NSW Police Association, Police Federation of Australia, and state counterparts argue that zero-tolerance provides clear enforcement standards and that impairment testing is subjective and legally vulnerable. The Police Federation of Australia's submission to the National Transport Commission in 2025 stated that "officers cannot be expected to make complex medical judgments at roadside" and that current oral fluid testing provides "objective, defensible evidence."

Patients' Advocacy Groups

Multiple patient organizations have formed specifically around this issue. Medicinal Cannabis Users Australia (MCUA), established in 2020, represents over 8,000 members and has coordinated legal challenges and parliamentary submissions. The organization's June 2026 survey of 2,400 patients found that 67% had modified or discontinued treatment due to driving concerns, and 43% reported using cannabis products without prescription to avoid documentation that could be used in traffic prosecutions. The Australian Patient Advocacy Alliance has documented over 300 cases where patients lost employment due to drug driving convictions despite holding valid prescriptions.

Legal and Regulatory Framework

Australia's medicinal cannabis driving laws operate through a complex interaction of federal therapeutic regulation and state-based traffic enforcement, creating jurisdictional tensions without clear constitutional resolution.

Federal Therapeutic Framework

The Therapeutic Goods Act 1989 (Cth) provides the constitutional basis for federal cannabis regulation through the Commonwealth's pharmaceutical benefits power. The Narcotic Drugs Act 1967 (Cth), as amended in 2016, establishes the licensing regime for cultivation and manufacture. Cannabis remains a Schedule 8 (Controlled Drug) and Schedule 4 (Prescription Only Medicine) substance under the Poisons Standard, requiring prescription by registered medical practitioners.

Patients access medicinal cannabis through three pathways: Special Access Scheme Category B (individual TGA approval for unapproved therapeutic goods), Authorised Prescriber pathway (doctor-level approval for specific patient cohorts), and clinical trials. All pathways require that products meet TGA manufacturing standards and that prescribers determine therapeutic necessity. Federal law contains no provisions regarding driving or operation of machinery beyond standard pharmaceutical labeling requirements.

State and Territory Traffic Laws

Each Australian jurisdiction has enacted drug driving offenses with similar structures but varying penalties and procedures:

Jurisdiction	Primary Legislation	Offense Provision	First Offense Penalty	Medical Defense
New South Wales	Road Transport Act 2013	Section 111	$603 fine, 3-month disqualification	None
Victoria	Road Safety Act 1986	Section 49(1)(bb)	$500 fine, 6-month disqualification	None
Queensland	Transport Operations (Road Use Management) Act 1995	Section 79(1A)	$431 fine, 1-9 month disqualification	None
South Australia	Road Traffic Act 1961	Section 47BA	$1,176 fine, 6-month disqualification	None
Western Australia	Road Traffic Act 1974	Section 64AC	$1,100 fine, 3-month disqualification	None
Tasmania	Road Safety (Alcohol and Drugs) Act 1970	Section 6AA	$1,560 fine, 3-month disqualification	Limited (since 2023)
Northern Territory	Traffic Act 1987	Section 26AAA	$1,000 fine, 6-month disqualification	None
Australian Capital Territory	Road Transport (Alcohol and Drugs) Act 1977	Section 13A	$3,200 fine, 6-month disqualification	None

All jurisdictions except Tasmania apply strict liability, meaning prosecution need only prove THC presence, not impairment or intent. Defenses available for other traffic offenses—such as necessity, duress, or honest and reasonable mistake—have been legislatively excluded for drug driving offenses.

Detection Methods and Thresholds

Roadside oral fluid testing uses immunoassay devices approved by the National Association of Testing Authorities. The Draeger DrugTest 5000 and Securetec DrugWipe devices detect THC at cutoff concentrations of 25 ng/mL in oral fluid. Positive roadside tests trigger confirmatory laboratory analysis using gas chromatography-mass spectrometry, with confirmation thresholds of 10 ng/mL for THC.

Critically, these thresholds detect THC metabolites that can persist for 24-72 hours after use in regular consumers, well beyond the 3-6 hour window of psychoactive impairment. Research by the National Drug and Alcohol Research Centre found that oral fluid tests can detect THC up to 34 hours after last use in daily medicinal cannabis patients, even when cognitive testing shows no impairment.

Constitutional Challenges

Several constitutional arguments have been raised but not definitively resolved. The inconsistency between federal therapeutic approval and state criminal prohibition raises questions under Section 109 of the Australian Constitution, which provides that federal law prevails over inconsistent state law. However, courts have consistently found no inconsistency because federal law permits therapeutic use while state law regulates driving conduct—distinct legal fields.

Discrimination arguments under state and federal anti-discrimination laws have also failed. In Carrall v South Australia Police (2019), the court found that drug driving laws do not discriminate on the basis of disability because they apply equally to all drivers regardless of medical status. The distinction between medicinal and recreational users was held to be a legitimate policy choice within state legislative power.

Workplace and Employment Law Intersection

The interaction with workplace drug testing creates additional complexity. The Fair Work Act 2009 (Cth) protects employees from adverse action based on disability, but employers can implement drug and alcohol policies as occupational health and safety measures. The Fair Work Commission has heard several cases where employees with medicinal cannabis prescriptions were dismissed following positive workplace drug tests. Decisions have been inconsistent, with some finding unfair dismissal and others upholding employer safety policies.

State-by-State Breakdown

New South Wales

New South Wales has the largest medicinal cannabis patient population and the most active reform debate as of June 2026. Approximately 78,000 NSW residents hold valid prescriptions. The Road Transport Act 2013 sections 111-112 create the offense of driving with prescribed illicit drugs present, with mandatory oral fluid testing powers under section 112A. First offenses carry automatic three-month license disqualification and $603 fines, with subsequent offenses increasing to six-month disqualification and potential imprisonment.

The NSW Parliament's consideration of the Medicinal Cannabis Patients (Road Safety) Bill 2026 represents the most comprehensive reform proposal in any jurisdiction. The bill would amend the Road Transport Act to create a new section 111A, providing that a person does not commit an offense if they hold a valid prescription, were not impaired at the time of driving, and can demonstrate compliance with prescriber directions. The bill includes provisions for secondary impairment testing using standardized field sobriety tests and cognitive assessment tools.

Transport for NSW data shows that in 2025, approximately 3,200 drivers were convicted of drug driving offenses involving THC detection. Of these, Transport for NSW estimates that 15-20% held valid medicinal cannabis prescriptions, though precise figures are not tracked. The NSW Police Force conducted 212,000 mobile drug tests in 2025, with a THC detection rate of 1.8%.

Victoria

Victoria pioneered drug driving laws and maintains the strictest enforcement regime. The Road Safety Act 1986 section 49(1)(bb) creates strict liability for driving with THC, methylamphetamine, or MDMA present. Victoria conducts approximately 150,000 roadside drug tests annually, the highest per capita rate in Australia. First offenses result in automatic six-month disqualification and $500 fines.

The Victorian Government has resisted reform despite the 2022 parliamentary inquiry recommendations. In March 2026, Victorian Roads Minister Melissa Horne stated that the government would not consider changes until "reliable impairment testing technology is available and validated." Victoria has approximately 62,000 medicinal cannabis patients, with patient advocacy groups reporting that driving law concerns are the primary barrier to treatment uptake.

Victoria is the only jurisdiction that has published research on medicinal cannabis patient driving outcomes. A 2024 Monash University study tracking 480 medicinal cannabis patients over 18 months found no statistically significant increase in crash involvement compared to matched controls, though the study noted limitations in sample size and self-reporting bias.

Queensland

Queensland's Transport Operations (Road Use Management) Act 1995 section 79(1A) creates drug driving offenses with penalties ranging from one to nine months disqualification for first offenses. Queensland conducts approximately 100,000 roadside drug tests annually. The state has approximately 45,000 medicinal cannabis patients as of June 2026.

The Queensland Government announced in April 2026 that it would establish a working group to examine medicinal cannabis driving issues, with reporting expected in late 2026. The working group includes representatives from Queensland Health, Department of Transport and Main Roads, Queensland Police Service, and patient advocacy groups. Queensland's approach has been characterized as "wait and see," monitoring developments in other jurisdictions before committing to reform.

South Australia

South Australia's Road Traffic Act 1961 section 47BA imposes the highest first-offense fines in Australia at $1,176, combined with six-month disqualification. South Australia conducts approximately 45,000 roadside drug tests annually. The state has approximately 18,000 medicinal cannabis patients.

South Australia has been the most resistant to reform, with the Marshall and Malinauskas governments both opposing changes. The SA Police Commissioner Grant Stevens stated in February 2026 that "zero-tolerance drug driving laws have been instrumental in reducing road trauma" and that medical exemptions would "undermine the deterrent effect." South Australian patient advocacy groups have focused on federal constitutional challenges rather than state legislative reform.

Western Australia

Western Australia's Road Traffic Act 1974 section 64AC creates drug driving offenses with three-month disqualification and $1,100 fines for first offenses. WA conducts approximately 55,000 roadside drug tests annually. The state has approximately 28,000 medicinal cannabis patients.

The WA Government has taken a middle position, neither actively pursuing reform nor categorically rejecting it. In May 2026, WA Transport Minister Rita Saffioti indicated openness to "evidence-based reform if other jurisdictions demonstrate workable models." Western Australia has the highest rate of regional medicinal cannabis patients, with approximately 65% of prescriptions issued to patients outside the Perth metropolitan area, making driving access particularly critical.

Tasmania

Tasmania's 2023 reform created a limited medical defense under the Road Safety (Alcohol and Drugs) Act 1970, but implementation has proven largely ineffective. The amendment allows defendants to present evidence of non-impairment, but the burden of proof remains on the defendant, requiring expert testimony that most patients cannot afford. In 18 months since implementation, only three defendants successfully used the defense.

Tasmania has approximately 8,500 medicinal cannabis patients. The Tasmanian Government commissioned a review of the 2023 reforms in early 2026, with preliminary findings suggesting that the defense mechanism requires substantial revision to be practically accessible. Tasmanian patient advocates have called for a reverse onus where prescription holders are presumed not impaired unless prosecution proves otherwise.

Northern Territory and Australian Capital Territory

The Northern Territory and Australian Capital Territory have smaller patient populations (approximately 3,200 and 4,800 respectively) and have not actively engaged with reform debates. Both jurisdictions have indicated they will follow national consensus if it emerges from larger states. The ACT's higher penalties ($3,200 first offense) reflect its general approach of higher fines combined with lower enforcement intensity.

Market and Business Implications

The driving law conflict directly impacts the commercial viability of Australia's medicinal cannabis industry, suppressing patient numbers and creating competitive disadvantages compared to international markets.

Australia's medicinal cannabis market reached AU$350 million in annual sales in 2025, with 47 licensed cultivators and manufacturers. Industry projections anticipated AU$1.2 billion by 2028, but these forecasts increasingly incorporate "driving law discounts" of 30-40% to account for patient deterrence. Medicinal Cannabis Industry Australia's 2026 market analysis found that driving law concerns suppress patient uptake by an estimated 40-50%, representing AU$400-500 million in foregone annual revenue.

The impact varies by product category. High-THC products face the greatest market suppression, with patients preferring CBD-dominant formulations that carry lower (though not zero) detection risk. This creates perverse therapeutic outcomes, as many conditions respond better to balanced THC:CBD ratios or THC-dominant products. Industry data shows that CBD-dominant products represent 68% of Australian sales compared to 35-40% in comparable markets like Germany and Canada, suggesting significant demand distortion.

Investment and Capital Flows

Australian cannabis companies have struggled to attract international investment compared to North American and European competitors, with driving law uncertainty cited as a key factor. Little Green Pharma, one of Australia's largest licensed producers, reported in its 2025 annual report that "regulatory uncertainty regarding patient driving rights continues to impact market growth projections and investor confidence." The company's market capitalization declined 23% in 2025 despite increasing production capacity.

Several international cannabis companies have delayed or abandoned Australian market entry. Canadian producer Canopy Growth cited "unresolved driving law conflicts" as a factor in its 2024 decision to deprioritize Australian expansion. The investment impact extends beyond cannabis-specific companies to ancillary sectors including testing laboratories, medical clinics, and pharmacy distribution networks.

Employment and Workplace Impacts

The intersection of medicinal cannabis, workplace drug testing, and driving requirements creates complex employment law issues. Industries with safety-sensitive positions—including transport, mining, construction, and healthcare—face particular challenges. Many employers maintain zero-tolerance drug policies that prohibit any cannabis use regardless of prescription status, while others have developed accommodation frameworks.

The Transport Workers Union estimates that over 15,000 commercial vehicle operators could benefit from medicinal cannabis for chronic pain and other conditions but cannot access treatment without losing employment. This creates workforce health implications, as workers may rely on opioid medications with greater impairment risks but no driving law conflicts. Some employers have begun advocating for driving law reform, recognizing that current frameworks push workers toward less safe alternatives.

Insurance Sector Implications

The Insurance Council of Australia has expressed concern that driving law reform could complicate liability determinations in motor vehicle accidents. Current frameworks provide clear-cut liability: any detectable THC establishes contributory negligence regardless of fault. Impairment-based frameworks would require case-by-case assessment of whether cannabis use contributed to crashes.

However, insurance industry analysis also recognizes potential benefits. Actuarial data from jurisdictions with impairment-based frameworks (including several U.S. states and Canadian provinces) shows no statistically significant increase in claim frequency or severity. Some insurers have indicated willingness to support reform if accompanied by robust impairment testing standards and clear liability frameworks.

Medical Practice Economics

Driving law conflicts impact medical practice patterns and clinic economics. Doctors report spending substantial consultation time discussing driving law risks rather than therapeutic issues. Some practitioners have stopped prescribing cannabis products entirely due to liability concerns and patient dissatisfaction when informed of driving restrictions.

Specialist medicinal cannabis clinics have emerged as a practice model, with over 120 dedicated clinics operating nationally as of June 2026. These clinics report that 30-40% of initial consultations result in patients declining treatment after learning about driving implications. Clinic operators have become active advocates for reform, arguing that current laws undermine evidence-based medical practice.

What Experts Say

Expert opinion on medicinal cannabis driving laws divides along disciplinary lines, with medical and scientific experts generally supporting reform while law enforcement and some road safety professionals defend zero-tolerance frameworks.

The National Drug and Alcohol Research Centre at the University of New South Wales has published extensively on cannabis and driving. Professor Iain McGregor, who leads the Centre's medicinal cannabis research program, has stated that current laws "conflate presence with impairment in ways that are scientifically indefensible." McGregor's research team found that cognitive impairment from therapeutic cannabis doses typically resolves within 3-6 hours, while detection windows extend to 24-72 hours in regular users. According to McGregor, this creates a situation where "patients are being prosecuted for driving safely."

The Australasian College of Road Safety has taken a more cautious position. College President Lauchlan McIntosh has said that while "there are legitimate concerns about current frameworks," any reform must ensure that "impaired drivers are detected and removed from roads." The College's 2025 position paper recommended substantial investment in impairment testing technology before policy changes, estimating that AU$50-80 million in research funding would be needed to develop and validate roadside impairment assessment tools.

Dr. Bastian Seidel, former president of the Royal Australian College of General Practitioners, has been a vocal reform advocate. Seidel has described the current situation as "untenable for medical practitioners" and argued that doctors should be able to certify patient fitness to drive based on clinical assessment, similar to frameworks for benzodiazepines and opioids. According to Seidel, the conflict between therapeutic judgment and automatic criminalization undermines the doctor-patient relationship and discourages appropriate prescribing.

Law enforcement perspectives emphasize practical enforcement challenges. Australian Federal Police Association President Alex Caruana has stated that impairment testing would create "subjective assessments vulnerable to legal challenge" and that current oral fluid testing provides "objective, scientifically defensible evidence." Police unions have consistently argued that any detectable THC represents unacceptable risk and that medical exemptions would create enforcement complexity.

Forensic toxicology experts have highlighted the limitations of current testing. Dr. Olaf Drummer, a leading Australian forensic toxicologist, has noted that "THC detection does not correlate reliably with impairment" and that "we are prosecuting people who pose no greater crash risk than the general population." Drummer's research has found that low-level THC presence (below 5 ng/mL blood concentration) shows no statistically significant association with crash causation when controlling for other factors.

International comparisons provide additional context. Professor Wayne Hall of the University of Queensland, who has studied cannabis policy internationally, has observed that "Australia is an outlier in applying zero-tolerance to medical cannabis patients" and that jurisdictions with impairment-based frameworks "have not experienced road safety deterioration." Hall has pointed to Canadian provinces and several U.S. states as models where medical cannabis patients can drive legally if not impaired, without measurable increases in crash rates.